Bold Moves

Deliver first-in-class science

Transform our go-to-market model

2020 saw the growth of Pfizer's leading biosimilars portfolio, allowing patients to access these potentially lower-cost therapies

Globally, there is a growing demand for savings and efficiencies across health care systems. This demand has been emphasized amid an unprecedented global pandemic, driving the need for more accessible and affordable solutions.

Biosimilars can help fill this need. As equally effective and often lower-cost options to their biological medicines, biosimilars can help increase patient access to potentially life-changing therapies and lower the overall cost of care. In fact, estimates show that potential savings from biosimilars range from up to $50 billion over five years to up to $250 billion over 10 years in the five major EU markets and the U.S.3,4

$50 - $250 billion​​​​​​​​​​​​

Potential savings from biosimilars range from $50 billion over five years to $250 billion over 10 years in the five major EU markets and the U.S.3,4

Pfizer is enthusiastic about the promise of biosimilars and wants to make this promise a reality. For more than 12 years, we have pioneered bringing high-quality biosimilars to patients around the world by applying expertise in biologics, investing significant resources and leveraging our deep understanding of how to navigate regulatory pathways.

Advancing the science of biosimilars.

In 2020, Pfizer became the first company to launch three oncology monoclonal antibody biosimilars in the U.S., Zirabev™ (bevacizumab-bvzr), Ruxience™ (rituximab-pvvr) and Trazimera™ (trastuzumab-qyyp), offering the medicines at a substantially discounted list price to the originator product. All three are highly similar versions of some of the most widely prescribed oncology therapies, collectively treating nine cancer types.

Pfizer today has the largest biosimilar portfolio in the U.S. and largest oncology biosimilars portfolio globally.1,2 Now, more than ever, we remain driven to fulfill its promise.


1Center for Drug Evaluation and Research. (n.d.). Biosimilar Drug Information. Retrieved February 01, 2021, from

​​​​​​​2How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline. (n.d.). Retrieved February 01, 2021, from

​​​​​​​3Delivering on the Potential of Biosimilar Medicines. (March 2016). IMS Institute for Healthcare Informatics.

​​​​​​​4Biosimilar Basics  For Patients [PDF]. (2018). American Pharmacists Association.

Discover more

Advances for a Potential First-in-Class Chronic OA Pain Treatment

Advancing Breakthroughs for Patients With NASH

Eucrisa, Now Starring Jessica Simpson

Working for Patients with Alopecia Areata

Advancing a Potential Breakthrough for Moderate to Severe Atopic Dermatitis

A Potentially Practice-Changing Approval in Advanced Urothelial Cancer

Addressing an Unmet Need for Certain Patients With BRAF-Mutant mCRC

Learning From Early Breast Cancer Studies to Drive Oncology Research Forward

Cancer Doesn’t Wait: Supporting Screenings During COVID-19

Positive Phase 1/2 Data at One Year for Hemophilia A Gene Therapy

Investigational Gene Therapy for Duchenne Muscular Dystrophy Achieves Exciting Milestones in 2020

Pfizer Vaccines Pipeline Includes Six Late-Stage Candidates

Pfizer Vaccines Launches​​​​​​​ Global Centers of Excellence Network

Progressing Maternal Vaccination Against Respiratory Syncytial Virus

Pfizer Pledges $100 Million Into New AMR Industry Fund

Partnering with Wellcome to Combat AMR in Sub-Saharan Africa

Expanding Access in China Through Health Insurance Innovation

Pfizer Invests in Biotechnology Innovation through the Pfizer Breakthrough Growth Initiative

Hospital Donations for COVID-19 Response

Pfizer Partners with BioNTech to Advance & Supply COVID-19 Vaccine​​​​​​​

Delivering on the Promise of Biosimilars

Driving Diversity in Our Research and Development​​​​​​​

Site Feature: Puurs, Belgium 

PGS Ingenuity Solves COVID-19 Cold Chain Storage Challenge​​​​​​​

Pfizer and Gilead Sciences Agree to Manufacture and Supply Remdesivir​​​​​​​

Key Medicine Supply and Public Policy During COVID-19

Pfizer Stands with Science

Five-Point Plan for Unprecedented Collaboration

COVID-19 Updates

Read the latest information about Pfizer’s COVID-19 vaccine on



Join the Conversation

Additional Information

Useful Links

The product information provided in this site is intended only for residents of the United States. The products discussed herein may have different product labeling in different countries.

Copyright © 2020-2021 Pfizer Inc.
All rights reserved

Explore our stories